A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Diabetic kidney disease remains the leading cause of end-stage kidney disease (ESKD), rising
in frequency in parallel with the epidemic of diabetes worldwide. The estimated lifetime risk
of kidney disease in persons with type 1 diabetes (T1D) has been reported to be as high as
50-70%, although risk may be lower in excellent care environments. Two previous studies have
suggested that a generic drug used to lower fats in blood (fenofibrate) may protect the
kidney from damage due to diabetes. These data, however, were obtained among people with type
2 diabetes with clinical characteristics optimized for cardiovascular studies. Thus, a
clinical trial specifically designed to evaluate the effects on the kidney is required to
firmly show that this drug can prevent kidney damage in T1D. The goals of the present pilot
study are to demonstrate the feasibility of such trial, gather essential information for
designing and planning this study, and generate preliminary data. To this end, 40
participants with T1D and early-to-moderate diabetic kidney disease (DKD), at high risk of
ESKD, will be enrolled at two clinical sites and assigned in a 1:1 ratio to treatment with
fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and
at the end of the study to evaluate the effect of fenofibrate.